What Is Semaglutide? Benefits, Research & Safety
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
UK summary: Licensed UK medicine (Ozempic for type 2 diabetes; Wegovy for chronic weight management). Prescription-only. Lawful access is through a registered UK prescriber and a regulated pharmacy. Counterfeit pens are a major UK safety issue.
Quick Facts
Overview
Semaglutide — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Licensed UK medicine (Ozempic for type 2 diabetes; Wegovy for chronic weight management). Prescription-only. Lawful access is through a registered UK prescriber and a regulated pharmacy. Counterfeit pens are a major UK safety issue.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: MHRA approved. Ozempic licensed for type 2 diabetes; Wegovy licensed for weight management.
- EU: EMA approved for type 2 diabetes (Ozempic) and weight management (Wegovy).
- Notes: Semaglutide is a fully approved prescription medication in the UK, EU, USA, and many other countries. It should only be obtained through legitimate medical channels and used under healthcare supervision.
05Approved medical uses
- Wegovy — UK weight management (NICE TA875)
- Ozempic — UK type 2 diabetes
- Rybelsus — UK type 2 diabetes (oral)
06Unapproved / promotional claims
- Cures type 2 diabetes
- Safe and effective for cosmetic / non-clinical weight loss in any BMI
- Reverses metabolic syndrome
- Equivalent to ‘research-grade semaglutide’ from online vials
07Common internet claims
- Skinny shot / weight-loss miracle
- Compounded semaglutide is the same as Wegovy at half the price
- Use Ozempic off-label for cosmetic weight loss
- Take any GLP-1 you can get hold of during a Wegovy shortage
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Causes substantial weight loss (~15% body weight)” | A | Yes | Low | Large human RCTs (STEP programme) show mean weight loss around 15% at 68 weeks for Wegovy 2.4 mg, with individual variation. |
| “Reduces cardiovascular events in eligible patients” | B | Yes | Low | Cardiovascular outcomes data exist; the magnitude and applicability depend on the specific population and indication. |
| “Available over-the-counter online — no prescription needed” | E | No | High | Semaglutide is a UK prescription-only medicine. Online sources selling it without a prescription operate outside UK law. |
| “Research-only semaglutide vials are equivalent to Wegovy” | E | No | High | Grey-market 'research' product is not verifiable as genuine pharma-grade semaglutide. Identity, purity, and dosing are unverified. |
| “No side effects — perfectly safe” | E | No | High | Common side effects are mostly gastrointestinal. Rarer serious risks exist. Always discuss with a prescriber. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Nausea, vomiting, diarrhoea, constipation (common, dose-dependent)
- Gallbladder disease — recognised class effect
- Pancreatitis — recognised but uncommon
- Contraindicated in pregnancy and breastfeeding
- Counterfeit pen risk via unlicensed supply chains
11Drug-interaction uncertainty
Drug-interaction picture documented in the prescribing information.
12Anti-doping status
13UK legal position
MHRA approved. Ozempic licensed for type 2 diabetes; Wegovy licensed for weight management.
14EU legal position
EMA approved for type 2 diabetes (Ozempic) and weight management (Wegovy).
15What this page cannot tell you
- Whether semaglutide is appropriate for your individual clinical picture.
- Whether a vial labelled ‘semaglutide’ from an online seller actually contains semaglutide.
- How off-label use for cosmetic weight loss compares clinically to the licensed indications.
- Whether you meet NICE TA875 NHS criteria — that needs a specialist assessment.
16Last reviewed
17Citation quality score
18Research gaps
- Long-term cardiovascular outcomes in patients without diabetes.
- Optimal duration of weight-management therapy and management of post-discontinuation regain.
- Specific safety data for adolescents and older adults.
- Population-level effects on related conditions (cardiovascular, renal, cognitive).
19Safer alternatives / established care pathways
- Licensed Wegovy or Mounjaro via NHS specialist service or GMC-registered private prescriber.
- Structured weight-management programmes (Tier 2 / Tier 3 services).
- Bariatric assessment for patients meeting NICE criteria.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Am I eligible for NHS GLP-1 access, or is private the appropriate route?
- What dose-escalation plan are you proposing and why?
- How will gastrointestinal side effects be managed?
- What should I do if I plan to stop the medicine — both for side effects and for weight regain?
- What should I check on the genuine packaging when I collect my prescription?
- If I notice a side effect, do I report it via you, NHS 111, or the Yellow Card scheme?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Significant weight loss averaging 15-17% of body weight in obesity trials
- 2Improved glycaemic control in type 2 diabetes
- 3Reduced HbA1c levels by 1-2 percentage points
- 4Cardiovascular risk reduction in high-risk patients
- 5Decreased appetite and food cravings
- 6Improved blood pressure and lipid profiles
- 7Potential benefits for non-alcoholic fatty liver disease
- 8Reduced waist circumference and visceral fat
Claim vs Evidence
How popular claims about Semaglutide stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Causes substantial weight loss (~15% body weight)” | A | Yes | Low | Large human RCTs (STEP programme) show mean weight loss around 15% at 68 weeks for Wegovy 2.4 mg, with individual variation. |
| “Reduces cardiovascular events in eligible patients” | B | Yes | Low | Cardiovascular outcomes data exist; the magnitude and applicability depend on the specific population and indication. |
| “Available over-the-counter online — no prescription needed” | E | No | High | Semaglutide is a UK prescription-only medicine. Online sources selling it without a prescription operate outside UK law. |
| “Research-only semaglutide vials are equivalent to Wegovy” | E | No | High | Grey-market 'research' product is not verifiable as genuine pharma-grade semaglutide. Identity, purity, and dosing are unverified. |
| “No side effects — perfectly safe” | E | No | High | Common side effects are mostly gastrointestinal. Rarer serious risks exist. Always discuss with a prescriber. |
Theoretical Dosing & Protocols
| Theoretical Dosage | For obesity: 2.4 mg weekly (Wegovy); For diabetes: 0.5-1 mg weekly (Ozempic) |
| Frequency | Once weekly subcutaneous injection; oral (Rybelsus) taken daily |
| Duration | Long-term/ongoing treatment typically required to maintain benefits |
| Notes | Semaglutide is a prescription medication and should only be used under medical supervision. Dosage is typically escalated gradually to reduce gastrointestinal side effects. Treatment decisions should be made with a qualified healthcare provider. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (once weekly)
- Oral tablet (once daily - Rybelsus)
| Half-Life | Stability |
|---|---|
| Approximately 7 days, enabling once-weekly administration | Pens should be stored refrigerated before first use; stable at room temperature for limited periods after |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nausea (especially during dose escalation)
- Vomiting
- Diarrhoea
- Constipation
- Abdominal pain
- Decreased appetite
- Fatigue
Rare Risks & Concerns
- Pancreatitis (inflammation of the pancreas)
- Gallbladder problems including gallstones
- Thyroid tumours (seen in rodent studies; relevance to humans uncertain)
- Hypoglycaemia (especially when combined with insulin or sulfonylureas)
- Acute kidney injury (usually related to dehydration from GI effects)
- Diabetic retinopathy complications (in patients with existing retinopathy)
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis
- Pregnancy and breastfeeding
- Severe gastrointestinal disease
- Type 1 diabetes
UK & EU Regulatory Context
🇬🇧 United Kingdom
MHRA approved. Ozempic licensed for type 2 diabetes; Wegovy licensed for weight management.
🇪🇺 European Union
EMA approved for type 2 diabetes (Ozempic) and weight management (Wegovy).
Clinical Studies Summary
STEP 1: Semaglutide in Adults with Overweight or Obesity
Landmark trial showing 14.9% weight loss with semaglutide 2.4 mg vs 2.4% with placebo over 68 weeks in adults with obesity.
SUSTAIN-6: Cardiovascular Outcomes with Semaglutide
Demonstrated 26% reduction in major adverse cardiovascular events in patients with type 2 diabetes at high cardiovascular risk.
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.
Potent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass. None is related to this paper. CSM recused himself from handling this paper.
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.
In this systematic review and meta-analysis, discontinuing GLP-1RA treatment led to a pooled overall mean weight regain of 2.20 kg in participants taking liraglutide and 9.69 kg in those patients prescribed semaglutide/tirzepatide. The proportion of weight regained was proportional to the amount originally lost.
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
GLP-1RAs are efficacious in treating adults with type 2 diabetes. Compared with the placebo, tirzepatide was the most effective GLP-1RA drug for glycaemic control by reducing haemoglobin A1c and fasting plasma glucose concentrations. GLP-1RAs also significantly improved weight management for type 2 diabetes, with CagriSema performing the best for weight loss.
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Our data show that s.c. tirzepatide had a more pronounced effect on HbA1c and weight reduction compared with s.c. semaglutide in people with type 2 diabetes. Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events.
Registered Trials & Regulatory Status
67 of 90 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.
Status: Not Yet Recruiting · 240 participants · Ministry of Health, Saudi Arabia
Conditions: Type 1 Diabetes Mellitus
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
Status: Not Yet Recruiting · 30 participants · Vanderbilt University Medical Center
Conditions: Duchenne Muscular Dystrophy (DMD)
Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study
Status: Not Yet Recruiting · 40 participants · Kirby Institute
Conditions: Methamphetamine Use Disorder
GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis
Status: Not Yet Recruiting · 396 participants · Peking Union Medical College Hospital
Conditions: Hypertriglyceridemia Induced Acute Pancreatitis, Recurrent Acute Pancreatitis, Pancreatitis Relapsing
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Status: Not Yet Recruiting · 80 participants · Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
Status: Not Yet Recruiting · 240 participants · Alain Dagher
Conditions: Class I/II Obesity
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
Status: Not Yet Recruiting · 956 participants · The United Bio-Technology (Hengqin) Co., Ltd.
Conditions: Type 2 Diabetes
Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus
Status: Not Yet Recruiting · 24 participants · Mapi Pharma Ltd.
Conditions: Diabete Type 2
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
Status: Not Yet Recruiting · 164 participants · Biophytis
Conditions: Muscle Wasting, Obesity & Overweight, Obesity
Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
Status: Not Yet Recruiting · 20 participants · Vivani Medical, Inc
Conditions: Obesity & Overweight
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy
Status: Not Yet Recruiting · 100 participants · Population Health Research Institute
Conditions: Ischemic Stroke
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
Status: Recruiting · 62 participants · Terrestrial Bio, Inc.
Conditions: Overweight and/or Obesity
Adverse event reports (FDA FAERS)
- nausea943
- vomiting835
- diarrhoea589
- off label use426
- fatigue396
- dyspnoea382
- weight decreased379
- drug ineffective374
- dizziness328
- headache305
FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Semaglutide?
Source research-grade Semaglutide from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Semaglutide
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Am I eligible for NHS GLP-1 access, or is private the appropriate route?
- What dose-escalation plan are you proposing and why?
- How will gastrointestinal side effects be managed?
- What should I do if I plan to stop the medicine — both for side effects and for weight regain?
- What should I check on the genuine packaging when I collect my prescription?
- If I notice a side effect, do I report it via you, NHS 111, or the Yellow Card scheme?
UK regulatory & safety context
Related Research Guides
Related Peptides
Liraglutide
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
Learn moreTesofensine
A triple monoamine reuptake inhibitor originally developed for neurological conditions, now researched for its potent effects on appetite suppression and weight loss.
Learn moreGLP-1
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
Learn moreTirzepatide
A first-in-class dual GLP-1 and GIP receptor agonist achieving unprecedented weight loss of up to 22% in clinical trials, approved for type 2 diabetes and obesity treatment.
Learn more